CSTL - Castle Biosciences Inc Stock Price, Fair Value and News

$27.53+0.44 (+1.62%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CSTL Price Action

Last 7 days

-4.6%

Last 30 days

-3.2%

Last 90 days

-12.5%

Trailing 12 Months

26.3%

CSTL RSI Chart

CSTL Valuation

Market Cap

771.0M

Price/Earnings (Trailing)

126.92

Price/Sales (Trailing)

2.47

Price/Free Cashflow

22.33

CSTL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CSTL Fundamentals

CSTL Revenue

Revenue (TTM)

311.9M

Rev. Growth (Yr)

39.5%

Rev. Growth (Qtr)

-1.4%

CSTL Earnings

Earnings (TTM)

6.1M

Earnings Growth (Yr)

132.86%

Earnings Growth (Qtr)

-74.56%

CSTL Profitability

Operating Margin

81.90%

Return on Equity

1.38%

Return on Assets

1.18%

Free Cashflow Yield

4.48%

CSTL Investor Care

Shares Dilution (1Y)

4.08%

Diluted EPS (TTM)

0.22

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	250.7M	287.6M	311.9M	0
2023	152.2M	167.5M	192.0M	219.8M
2022	98.1M	110.2M	123.7M	137.0M
2021	68.0M	78.1M	86.3M	94.1M
2020	60.6M	62.5M	63.0M	62.6M
2019	27.8M	34.6M	45.7M	51.9M
2018	0	0	0	22.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Castle Biosciences Inc

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

CEO	Mr. Derek J. Maetzold
WEBSITE	https://castlebiosciences.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	582

Castle Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Castle Biosciences Inc? What does CSTL stand for in stocks?

CSTL is the stock ticker symbol of Castle Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Castle Biosciences Inc (CSTL)?

As of Fri Dec 20 2024, market cap of Castle Biosciences Inc is 771.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CSTL stock?

You can check CSTL's fair value in chart for subscribers.

Is Castle Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether CSTL is over valued or under valued. Whether Castle Biosciences Inc is cheap or expensive depends on the assumptions which impact Castle Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CSTL.

What is Castle Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, CSTL's PE ratio (Price to Earnings) is 126.92 and Price to Sales (PS) ratio is 2.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CSTL PE ratio will change depending on the future growth rate expectations of investors.